The markets are forward looking and the bod have made it easy here for a retrace by giving the markets a 6 month timeline to test against Covid in the lab, add in the Pfizer vaccine and 90% effective that’s one hell of a headliner and paves the path for the Oxford vaccine to be successful with many others following in the coming weeks.
Historically we sit below Quoted Datas bottom valuation which would make things really unpleasant here it happens again.
TLL Pharma's JAK1/TYK2 looks to be competitive and well patented but there is limited data, its finished pre-clinical and is nearing the end of its P1 trial in healthy adults the same path as SDC-1801 should start next year, its IC50 looks good on paper. https://ard.bmj.com/content/79/Suppl_1/252.1 P1 Status: https://clinicaltrials.gov/ct2/show/NCT04243083
It's certainly going to be a bumpy ride that's for sure, dont like the fact they mentioned the 6 months for covid lab testing as will only make for bigger swings so back to waiting on Sierra to do something with SRA737 or return it thinking they probably have 12 months from final data so April / May next year at the outside for news there.
Capital Gains Tax isnt as bad as some think it might be; use the Gov calculator (scroll down the page) and have a play around.
https://www.gov.uk/tax-sell-shares/work-out-your-gain
If you are a normal rate tax payer earning say £35k a year and you purchased £20k's worth of Sareum shares and you sell them for £40k = £20k profit you you would only pay £770 in Capital Gains Tax.
(Any sale of shares including at the time of a bed and isa are liable for Capital Gains Tax apart from any gains from shares once inside an isa)
My guess is the grant is a fair way priced in as a date for news was given in advance and hopefully the grant amount will be in the £200k+ area but the SP will suffer if we don’t get one, its small and we have to part fund it or its delayed. I don’t think the grant was ever part of the Bods plan so hoping they put in some effort on the application.
Looking around at the competitive landscape for TYK2 this new one stands out; an oral JAK1/TYK2 from TLL Pharmaceutical first mentioned as far as I can see as a competitor for SDC-1801 in autoimmune in Junes Quoted Data report. Looks similar to SDC-1801 in that it’s avoiding JAK2/JAK3
https://ard.bmj.com/content/79/Suppl_1/252.1
Entered a Phase 1 in Jan 2020 a SAD/MAD study same route as John is stating for SDC-1801 at the presentation.
https://clinicaltrials.gov/ct2/show/NCT04243083
Noted a few other TYK2’s close to finishing preclinical but this one looks like a potential competitor anyone researched this one……….Rmm anyone thoughts on its IC values for TYK2/JAK1 compared to SDC-1801
This is still under QuotedDatas Junes price that has nothing priced in for Covid-19 / SRA737 / FLT3 + Aurora. Since June we have had Lupus Report, SDC-1802 Patent & Baricitinib Significant Effect on Recovery Time in Covid-19.
No speeding tickets to come rerate underway this is still undervalued here before any news.....
If Covid-19 funding can be obtained, such a move could accelerate the clinical development timeline of SDC-1801 and could Catalyse a Substantial Increase in Value.
If such grant applications are awarded, SDC-1801 could join a group of drugs – including a number of JAK inhibitors – that have been fast-tracked into trials for COVID-19 As a dual TYK2/JAK1 inhibitor, SDC-1801 could be more effective and/or better tolerated than these similar compounds in treating COVID-19.
Assuming such funding can be obtained, it is possible that a clinical development programme for SDC-1801 in COVID-19 could be started in patients quickly, perhaps within months of first-in-person studies (single and multiple ascending dose in healthy volunteers). This would mirror the approach Theravance has taken with TD-0903.
Sadoldgit This is where Tim and John excel they always put safety first and foremost and still create effective targeted compounds. Even our CHK1 SRA737 future is extremely bright because upcoming combination treatments will require drugs with extremely good safety and efficacy profiles which we have and now the potential class leader.